Search Results

You are looking at 1 - 10 of 130 items for :

  • "erlotinib" x
  • All content x
Clear All
Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

mutations are identified. 4 This report describes a patient with PDAC whose tumor was characterized by an exon 19 deletion and who experienced a sustained response to erlotinib. Case Summary A 57-year-old Caucasian man with type II diabetes mellitus

Full access

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

, but prompted consideration for treatment with an EGFR inhibitor. She was subsequently started on erlotinib, an anti-EGFR small tyrosine kinase inhibitor, at 150 mg orally daily and bevacizumab at 15 mg/kg intravenously every 3 weeks. She tolerated

Full access

Bruce Brockstein, Mario Lacouture, and Mark Agulnik

Edited by Kerrin G. Robinson

erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck . J Clin Oncol 2004 ; 22 : 77 – 85 . 41. Pollack VA Savage DM Baker DA

Full access

Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk

coadministered with cisplatin in patients whose tumors had a cisplatin-resistant phenotype. 29 Table 1 GOG 240 Schema * Because of this historical background, a study was performed with erlotinib (an oral tyrosine kinase inhibitor) in patients

Full access

Philip E. Lammers, Christine M. Lovly, and Leora Horn

hypothesized that the clone expressing the T790M mutation might be low prevalence given the patient’s lack of previous therapy, and therefore decided that the patient might yet derive benefit from erlotinib therapy. The patient was started on erlotinib, 150

Full access

Barbara Burtness, Milan Anadkat, Surendra Basti, Miranda Hughes, Mario E. Lacouture, Joan S. McClure, Patricia L. Myskowski, Jennifer Paul, Clifford S. Perlis, Leonard Saltz, and Sharon Spencer

erlotinib . Clin Cancer Res 2006 ; 12 ( 3 Pt 1 ): 839 – 844 . 15 Moore MJ Goldstein D Hamm J . Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer

Full access

Carrie Zornosa, Jonathan L. Vandergrift, Gregory P. Kalemkerian, David S. Ettinger, Michael S. Rabin, Mary Reid, Gregory A. Otterson, Marianna Koczywas, Thomas A. D'Amico, Joyce C. Niland, Rizvan Mamet, and Katherine M. Pisters

with bevacizumab (n = 199), 1% with erlotinib (n = 11), and less than 1% with cetuximab (n = 4). Institutional use of bevacizumab ranged from 12% to 29%, and overall use remained stable across the study period ( P for trend = .58). A minority of

Full access

Kevin S. Scher, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, and Karen L. Reckamp

, revealing an exon 19 deletion. After extensive discussion with the patient and her informed family, the patient’s neoadjuvant therapy was changed to erlotinib at 150 mg/d in mid-February 2010. She tolerated the therapy well, with minimal rash and fatigue. CT

Full access

Keith D. Eaton and Renato G. Martins

built on these initial results to improve the therapeutic efficacy of conventional chemotherapy. Second-line chemotherapy with docetaxel, 3 pemetrexed, 4 or erlotinib 5 improves survival and quality of life (QOL) for patients with NSCLC

Full access

Helena A. Yu and Gregory J. Riely

. First-Generation EGFR Tyrosine Kinase Inhibitors Gefitinib and erlotinib were the first EGFR tyrosine kinase inhibitors (TKIs) that were approved for the treatment of patients with non–small cell lung cancer (NSCLC). These drugs inhibit kinase activity